Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia. Article uri icon

Overview

publication date

  • February 10, 2019

Research

keywords

  • Antineoplastic Agents
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Pyrazoles
  • Pyrimidines
  • Tumor Lysis Syndrome

Identity

Scopus Document Identifier

  • 85061447149

Digital Object Identifier (DOI)

  • 10.1111/bjh.15791

PubMed ID

  • 30740654

Additional Document Info

volume

  • 186

issue

  • 1